Physician profile
Sharma Atkinson-Staten
NPI 1164811576
$260.37
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $186 · 2022: $74.41.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $63.77 | 2021-2022 | |
| Nevro Corp. | $49.90 | 2021-2022 | |
| Abbvie INC. | $38.34 | 2021-2022 | |
| Abbott Laboratories | $23.01 | 2021 | |
| Medtronic, INC. | $22.73 | 2021 | |
| Boston Scientific Corporation | $21.85 | 2022 | |
| Supernus Pharmaceuticals, INC. | $14.59 | 2021 | |
| Biodelivery Sciences International, INC. | $13.87 | 2021 | |
| Redhill Biopharma INC. | $12.31 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharma Atkinson-Staten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.